BCL2 interacting protein 3 pseudogene 35Genealiases: []
Q-omics provides the consensus-scored BNIP3P35 profile across patient tissues and cancer cell-line models. BNIP3P35 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, BNIP3P35 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, BNIP3P35 RNA expression shows 7,623 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight PAAD, HNSC, and COAD as cancer lineages where BNIP3P35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P35 survival associations across molecular data types. BNIP3P35 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P35 RNA expression–survival associations across cancer types. High BNIP3P35 expression shows unfavorable associations in PAAD, MESO, COAD, KIRC, UCEC and LGG. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for BNIP3P35 RNA expression.
This table summarizes BNIP3P35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P35 shows lower tumor expression in THCA and higher tumor expression in HNSC. The HNSC box plot shows higher BNIP3P35 RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p = .048).
This table shows molecular features associated with BNIP3P35 in patient tissues and cancer cell lines. In patient samples, BNIP3P35 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
